Loading…
Innate Pharma S.A. is projected to decline to $1.67 by 2027, a -5% move from its current price of $1.75. IPHA is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.65 | $1.75 | $1.86 | +0.06% |
| May 30 | $1.61 | $1.75 | $1.90 | +0.11% |
| May 31 | $1.58 | $1.75 | $1.94 | +0.17% |
| Jun 1 | $1.56 | $1.75 | $1.97 | +0.22% |
| Jun 2 | $1.54 | $1.75 | $2.00 | +0.28% |
| Jun 3 | $1.52 | $1.76 | $2.02 | +0.33% |
| Jun 4 | $1.51 | $1.76 | $2.05 | +0.39% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.51 | $1.76 | $2.05 | +0.39% |
| Week 2 | $1.42 | $1.76 | $2.19 | +0.78% |
| Week 3 | $1.36 | $1.77 | $2.31 | +1.17% |
| Week 4 | $1.31 | $1.78 | $2.42 | +1.57% |
| Week 5 | $1.26 | $1.78 | $2.52 | +1.96% |
| Week 6 | $1.23 | $1.79 | $2.61 | +2.36% |
| Week 7 | $1.20 | $1.80 | $2.70 | +2.76% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells.
In addition, the company develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, a BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A.
was incorporated in 1999 and is based in Marseille, France.
Innate Pharma S.A. (IPHA) is a biotechnology company focused on cancer immunotherapies.
The stock trades at current price $1.83 with a market cap of $171.84M, and it is ranked 3935.
The year-by-year forecast shows upside potential, with 2026 average at $1.83 and notable progression toward higher price targets, including 2029 average $2.28, 2030 average $2.80 (max $4.89), 2035 average $3.20, 2040 average $3.53, and 2050 average $7.06 with a max of $16.24. The implied ROI by 2050 is 285.9%, and sentiment shifts to BULLISH from 2029 onward.
A major floor 51.8% below — a decisive break under it would weaken the trend.
The nearest floor, 24.6% below — buyers have tended to step in here.
The nearest ceiling, 28.6% above — a clean break opens room to run.
A major ceiling 54.5% above — clearing it would confirm fresh momentum.
Key IPHA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IPHA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.89 | Sell | $1.83 | Sell |
| MA 10 | $1.93 | Sell | $1.83 | Sell |
| MA 20 | $1.68 | Buy | $1.74 | Buy |
| MA 50 | $1.51 | Buy | $1.63 | Buy |
| MA 100 | $1.61 | Buy | $1.64 | Buy |
| MA 200 | $1.79 | Sell | $1.74 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.77 | Neutral |
| Stoch RSI (14) | 31.08 | Neutral |
| CCI (20) | 17.27 | Neutral |
| Williams %R (14) | -53.76 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | 24.11 | Buy |
| Bollinger %B (20,2) | 0.56 | Neutral |
| Stochastic %K (14) | 46.24 | Neutral |
| TRIX (15) | 1.06 | Buy |
| Awesome (5,34) | 0.29 | Buy |
| Ultimate (7,14,28) | 44.89 | Neutral |
| Momentum (10) | 0.39 | Buy |
| Aroon Osc (25) | 12.00 | Buy |
| Hull MA (9) | 1.73 | Buy |
| ADX (14) | 15.96 | Neutral |
| ATR (14) | 0.13 | Info |
The near-term technical picture is bullish with RSI14 at 50.
Key moving-average levels show SMA50 at $1.50 and SMA200 at $1.80, providing a framework for short-term price action. The stock sits above a support level at $1.32 and faces resistance at $2.25, shaping a clear range in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.17 | $1.75 | $1.97 | 0% | Neutral | |
| $1.20 | $1.67 | $2.51 | -5% | Neutral | |
| $1.28 | $1.89 | $3.02 | +8% | Neutral | |
| $1.38 | $2.15 | $3.60 | +23% | Bullish | |
| $1.61 | $2.61 | $4.56 | +49% | Bullish | |
| $1.47 | $2.50 | $4.51 | +43% | Bullish | |
| $1.32 | $2.34 | $4.35 | +34% | Bullish | |
| $1.24 | $2.28 | $4.36 | +31% | Bullish | |
| $1.10 | $2.12 | $4.14 | +21% | Bullish | |
| $1.48 | $2.96 | $5.92 | +69% | Bullish | |
| $1.50 | $3.32 | $7.31 | +90% | Bullish | |
| $2.94 | $6.54 | $15.05 | +274% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.17 | $1.75 | $2.07 | +0.00% |
| June 2026 | $1.51 | $1.81 | $2.25 | +3.29% |
| July 2026 | $1.51 | $1.84 | $2.35 | +1.84% |
| August 2026 | $1.37 | $1.69 | $2.19 | -8.32% |
| September 2026 | $1.27 | $1.58 | $2.09 | -6.13% |
| October 2026 | $1.28 | $1.62 | $2.16 | +1.97% |
| November 2026 | $1.22 | $1.56 | $2.11 | -3.54% |
| December 2026 | $1.12 | $1.44 | $1.97 | -7.81% |
Click any year to see its month-by-month IPHA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The IPHA price prediction for 2026 points to an average of $1.75 (low $1.17, high $1.97) — a potential gain of 0% on today's $1.75. A consolidation phase looks the most probable path here.
In 2027, IPHA is projected to trade between $1.20 and $2.51, averaging $1.67 — a potential decline of -5% from today's $1.75. That is -5% versus the projected 2026 average. Price action looks broadly range-bound.
Innate Pharma S.A.'s 2028 outlook centres on $1.89, within a $1.28 to $3.02 range. That is up +13% on the projected 2027 average. That marks a +8% change versus current levels. A consolidation phase looks the most probable path here.
By 2029, IPHA could reach as high as $3.60, with a base case around $2.15 and support toward $1.38 — roughly +23% from $1.75. Momentum favours further upside here.
Expect IPHA to range from $1.61 to $4.56 through 2030. The $2.61 average target implies a +49% move from current prices. That is up +22% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The IPHA price prediction for 2031 points to an average of $2.50 (low $1.47, high $4.51) — a potential gain of +43% on today's $1.75. Momentum favours further upside here.
In 2032, IPHA is projected to trade between $1.32 and $4.35, averaging $2.34 — a potential gain of +34% from today's $1.75. That is -7% versus the projected 2031 average. Buyers look set to stay in control over this stretch.
Innate Pharma S.A.'s 2033 outlook centres on $2.28, within a $1.24 to $4.36 range. That is -2% versus the projected 2032 average. That marks a +31% change versus current levels. Momentum favours further upside here.
By 2034, IPHA could reach as high as $4.14, with a base case around $2.12 and support toward $1.10 — roughly +21% from $1.75. Buyers look set to stay in control over this stretch.
Expect IPHA to range from $1.48 to $5.92 through 2035. The $2.96 average target implies a +69% move from current prices. That is up +40% on the projected 2034 average. Momentum favours further upside here.
The IPHA price prediction for 2040 points to an average of $3.32 (low $1.50, high $7.31) — a potential gain of +90% on today's $1.75. Buyers look set to stay in control over this stretch.
In 2050, IPHA is projected to trade between $2.94 and $15.05, averaging $6.54 — a potential gain of +274% from today's $1.75. That is up +97% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in IPHA today (≈ 571.428571 IPHA) could be worth
$3,738.3
+$2,738.3 (+274%) by 2050 · US Dollar
Based on the average projected IPHA price of $6.54 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IPHAwould be worth at today's price.
$1,000 invested in IPHA on May 27, 2025 (≈ 462.962945 IPHA) would be worth
$810.19
-$189.81 (-19.0%) today · 0.81× · US Dollar
Based on a IPHA entry price of $2.16 vs. today's $1.75.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.2 | $795.45 | -20.5% |
| 1 month ago | $1.4 | $1,250 | +25.0% |
| 3 months ago | $1.74 | $1,005.75 | +0.6% |
| 6 months ago | $1.95 | $897.44 | -10.3% |
| 1 year ago | $2.16 | $810.19 | -19.0% |
| All time (5.0y) ago | $3.72 | $470.43 | -53.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IPHA forecast.
Our base-case forecast reaches $3.50 around 2050.
Implied market cap at $3.50: $328.66M
The multi-year forecast suggests a shift from NEUTRAL in 2026-2028 to BULLISH in 2029 and beyond, indicating a potential upside path over time.
By 2030, the average forecast price is $2.80 with a max of $4.89 and a ROI of 53.1%.
By 2040, the average forecast price is $3.53 with a max of $7.76 and a ROI of 92.6%.
By 2050, the average forecast price is $7.06 with a max of $16.24 and a ROI of 285.9%, with sentiment labeled BULLISH. These figures reflect estimates, not guarantees, and involve substantial uncertainty over long horizons.
Tap a question to reveal the answer.
In 2030 the average forecast price is $2.80, with a low of $1.72 and a high of $4.89, a ROI of 53.1%, and a BULLISH sentiment.
Forecasts show upside potential, with ROI rising to 24.4% in 2029, 53.1% in 2030, and 285.9% by 2050, but some years are labeled NEUTRAL and outcomes are not guaranteed.
Yes. The max forecasts reach $6.41 in 2035, $7.76 in 2040, and $16.24 in 2050, so $5 is within the forecast range.
$1.23 to $2.73.
Current price is $1.83 and market cap is $171.84M.
Innate Pharma S.A. Community Discussion
0Share your Innate Pharma S.A. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.